Is CureVac NV overvalued or undervalued?

As of 13 June 2025, the valuation grade for CureVac NV has moved from very attractive to attractive. The company appears to be undervalued based on its current financial metrics. Key ratios include a P/E ratio of 5, an EV to EBITDA of 1.90, and a PEG ratio of 0.03, which suggests significant growth potential relative to its price.
In comparison to its peers, CureVac NV's P/E ratio is notably lower than Supernus Pharmaceuticals, which has a P/E of 28.13, indicating that CureVac may be undervalued in the market. Additionally, CureVac's EV to EBIT ratio of 2.08 further supports this undervaluation narrative when compared to industry standards. Recent stock performance shows that CureVac has outperformed the S&P 500 over the past year, with a return of 65.49% compared to the index's 10.26%, reinforcing the attractiveness of its current valuation.